This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
13, 2025 Research from Cedars-Sinai investigators and collaborators at other leading medical institutions is helping to provide more treatment options to people living with tricuspid valve disease. Catheter-based procedures offer an alternative for patients who are not candidates for open-heartsurgery. Image by Getty.
Image courtesy of Henry Ford Health milla1cf Wed, 02/21/2024 - 19:07 February 21, 2024 — An 80-year-old woman from Frankenmuth, Michigan is the first Henry Ford Health structural heart disease patient—and the first ever in Michigan—to receive a new transcatheter heartvalve device for treating severe tricuspid regurgitation.
The Medtronic Evolut TAVR platform includes devices less invasive than traditional open-heartsurgery for the treatment of symptomatic severe aortic stenosis. “At At Medtronic, we continue to emphasize that valve design matters. mmHg TAVR; 11.8
13, 2025 Research from Cedars-Sinai investigators and collaborators at other leading medical institutions is helping to provide more treatment options to people living with tricuspid valve disease. Catheter-based procedures offer an alternative for patients who are not candidates for open-heartsurgery. Image by Getty.
We organize all of the trending information in your field so you don't have to. Join thousands of users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Cardiothoracic 
52 
Let's personalize your content